Lakefront Biotherapeutics NV (LKFT)
NASDAQ: LKFT · Real-Time Price · USD
29.50
+0.66 (2.29%)
At close: Jun 26, 2026, 4:00 PM EDT
29.48
-0.02 (-0.07%)
After-hours: Jun 26, 2026, 4:10 PM EDT
LKFT Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for LKFT stock have an average target of 25, with a low estimate of 22 and a high estimate of 28. The average target predicts a decrease of -15.25% from the current stock price of 29.50.
Analyst Consensus: Sell
* Price targets were last updated on May 13, 2026.
Analyst Ratings
The average analyst rating for LKFT stock from 4 stock analysts is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.
Recommendation Trends
| Rating | Dec '25 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 0 | 0 | 1 | 1 |
| Total | 5 | 4 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $28 | Hold | Maintains | $28 | -5.08% | May 13, 2026 |
| Morgan Stanley | Morgan Stanley | Sell Maintains $22 | Sell | Maintains | $22 | -25.42% | Mar 16, 2026 |
Financial Forecast
Revenue This Year
150.46M
from 1.11B
Decreased by -86.47%
Revenue Next Year
145.26M
from 150.46M
Decreased by -3.46%
EPS This Year
-2.87
from 10.21
EPS Next Year
-4.01
from -2.87
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 299.3M | 274.0M | |
| Avg | 150.5M | 145.3M | |
| Low | 20.1M | 20.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -73.1% | 82.1% | |
| Avg | -86.5% | -3.5% | |
| Low | -98.2% | -86.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -2.68 | -3.05 | |
| Avg | -2.87 | -4.01 | |
| Low | -3.05 | -4.97 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.